Press Release: Wyeth Pharmaceuticals Announces Organizational Change

Wyeth Pharmaceuticals Announces Organizational Change COLLEGEVILLE, Pa., February 22, 2007 -- Wyeth Pharmaceuticals, a division of Wyeth , announced today the appointment of Geno Germano, 46, to President - U.S. and General Manager, Wyeth Pharmaceuticals. In this new role, Mr. Germano will continue to report to Mr. Joseph Mahady, newly appointed President - Global Business, Wyeth Pharmaceuticals and Senior Vice President, Wyeth. Mr. Germano joined Wyeth in 1984 as a sales representative and has held positions of increasing responsibility in Sales, Marketing, Business Development and General Management, including Managing Director, Wyeth Australia and New Zealand; Executive Vice President and General Manager for Wyeth Global Vaccines; and most recently, Executive Vice President, Pharmaceutical Business Unit. Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health. CONTACT: Media: Douglas Petkus, +1-973-660-5218, or Investor: JustinVictoria, +1-973-660-5340, both of Wyeth

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.